SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models.

ABSTRACT:

Purpose

Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults with a median overall survival of only 14.6 months despite aggressive treatment. While immunotherapy has been successful in other cancers, its benefit has been proven elusive in GBM, mainly due to a markedly immunosuppressive tumor microenvironment. SARS-CoV-2 has been associated with the development of a pronounced central nervous system (CNS) inflammatory response when infecting different cells including astrocytes, endothelial cells, and microglia. While SARS-CoV2 entry factors have been described in different tissues, their presence and implication on GBM aggressiveness or microenvironment has not been studied on appropriate preclinical models.

Methods

We evaluated the presence of c

SUBMITTER: Suarez-Meade P 

PROVIDER: S-EPMC9808689 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature